Gönen: Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin-LL37, and ICAM1

Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin-LL37, and ICAM1

Gönen et al., Nutrients, doi:10.3390/nu13114047

Gönen et al., Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2).., Nutrients, doi:10.3390/nu13114047

Nov 2021 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 867 hospitalized COVID-19 patients in Turkey, showing worse outcomes with vitamin D deficiency (without statistical significance); followed by a prospective study of 210 patients with vitamin D supplementation for those that were deficient, showing significantly lower mortality compared to the retrospective study without treatment.

Important missing comments or errors? Let us know.

risk of death, 65.8% lower, RR 0.34, p = 0.62, high D levels (≥12ng/mL) 1 of 80 (1.2%), low D levels (<12ng/mL) 3 of 82 (3.7%), NNT 42, retrospective study.

risk of ICU admission, 16.9% lower, RR 0.83, p = 1.00, high D levels (≥12ng/mL) 4 of 77 (5.2%), low D levels (<12ng/mL) 5 of 80 (6.2%), NNT 95, retrospective study.

hospital stay >8 days, 21.1% lower, RR 0.79, p = 0.11, high D levels (≥12ng/mL) 40 of 78 (51.3%), low D levels (<12ng/mL) 52 of 80 (65.0%), NNT 7.3, retrospective study.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Gönen et al., 12 Nov 2021, retrospective, Turkey, peer-reviewed, 20 authors, dosage varies.

Contact: karraspiros@yahoo.gr, duygugezenak@iuc.edu.tr, duygugezenak@gmail.com, erdinc.dursun@iuc.edu.tr, erdincdu@gmail.com.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Vitamin D All

Abstract: nutrients Article Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin-LL37, and ICAM1 Mustafa Sait Gönen 1 , Merve Alaylıoğlu 2 , Emre Durcan 1 , Yusuf Özdemir 3 , Serdar Şahin 1 , Dildar Konukoğlu 4 , Okan Kadir Nohut 5 , Seval Ürkmez 6 , Berna Küçükece 7 , İlker İnanç Balkan 3 , H. Volkan Kara 8 , Şermin Börekçi 9 , Hande Özkaya 1 , Zekayi Kutlubay 10 , Yalım Dikmen 6 , Yılmaz Keskindemirci 11,12 , Spyridon N. Karras 13, * , Cedric Annweiler 14,15 , Duygu Gezen-Ak 2, * and Erdinç Dursun 2,16, * 1 2 3 Citation: Gönen, M.S.; Alaylıoğlu, M.; Durcan, E.; Özdemir, Y.; Şahin, S.; 4 Konukoğlu, D.; Nohut, O.K.; Ürkmez, S.; Küçükece, B.; Balkan, İ.İ.; et al. 5 Rapid and Effective Vitamin D Supplementation May Present Better 6 Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin-LL37, and ICAM1. 7 8 Nutrients 2021, 13, 4047. https:// doi.org/10.3390/nu13114047 9 Academic Editors: Maria 10 Luz Fernandez, Andrea Fabbri and Sara Gandini Received: 15 September 2021 Accepted: 11 November 2021 Published: 12 November 2021 Publisher’s Note: MDPI stays neutral 11 12 13 14 15 with regard to jurisdictional claims in published maps and institutional affil- 16 iations. * Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Endocrinology and Metabolism Unit, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; sait.gonen@iuc.edu.tr (M.S.G.); dr.durcan@hotmail.com (E.D.); srdr_shn@hotmail.com (S.Ş.); hmba@iuc.edu.tr (H.Ö.) Brain and Neurodegenerative Disorders Research Laboratories, Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; merve.alaylioglu@hotmail.com Department of Infectious Diseases and Clinical Microbiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; ozdemiryusufemre1990@gmail.com (Y.Ö.); ilkerinancbalkan@hotmail.com (İ.İ.B.) Department of Medical Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; dkonuk@istanbul.edu.tr Fikert Biyal Biochemistry Laboratory, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; okannohut@hotmail.com Department of Anesthesiology and Reanimation, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; seval.urkmez@istanbul.edu.tr (S.Ü.); ydikmen@iuc.edu.tr (Y.D.) Cerrahpasa Hospital Pharmacy Unit, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; bernakucukece11@gmail.com Department of Thoracic Surgery, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; volkan_kara@yahoo.com Department of Pulmonary Diseases, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; borekcisermin@gmail.com Dermatology and Venerology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; zekayikutlubay@hotmail.com General Directorate of Hospitals, Istanbul University-Cerrahpasa, Istanbul..

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit